Delaware (State or other jurisdiction of incorporation or organization) |
005-79588 (Commission File Number) |
62-1715807 (I.R.S. Employer Identification No.) |
ITEM 8.01 | Other Events. | |
On February 23, 2009, GTx, Inc. issued a press release announcing that it has initiated a Phase I clinical trial for GTx-758, an oral luteinizing hormone (LH) inhibitor to treat men with advanced prostate cancer, a copy of which is furnished as Exhibit 99.1 to this Current Report. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double blind, placebo controlled design in healthy male volunteers. |
ITEM 9.01 | Financial Statements and Exhibits. | |
(c) Exhibits |
Exhibit | ||
Number | Description | |
99.1
|
Press Release issued by GTx, Inc. dated February 23, 2009 |
GTx, Inc. |
||||
Date: February 23, 2009 | By: | /s/ Henry P. Doggrell | ||
Name: | Henry P. Doggrell | |||
Title: | Vice President, General Counsel and Secretary |